Nystatin STADA 500,000 I.E. tablets

Nystatin STADA 500,000 I.E. is a pharmaceutical product used for the topical intestinal treatment of yeast infections, specifically those caused by Candida albicans. The product is identified by the German Pharmaceutical Central Number (PZN) 19240072, which corresponds to the 50-tablet pack size of the coated tablets. This medication is primarily used to treat fungal overgrowth in the digestive tract, often arising as a secondary effect of antibiotic or corticosteroid therapy.

The brand STADA has a long heritage dating back to 1895 in Germany, where it began as a cooperative of pharmacists. Today, the brand is managed by STADA Arzneimittel AG, headquartered in Bad Vilbel, Germany. While the company was historically German-owned, it underwent a significant ownership change in 2017 when it was acquired by private equity firms Bain Capital and Cinven. In late 2025, it was announced that a majority stake would be sold to CapVest Partners LLP, a London-based private equity firm, transitioning the ultimate ownership as the brand moves into 2026.

Manufacturing for STADA's core pharmaceutical lines is heavily centered in Europe, with primary facilities in Germany. The brand operates globally, providing a wide range of generic and specialty healthcare products under its Consumer Health and Generics divisions. In Germany, the product is distributed via STADA Consumer Health Deutschland GmbH.